MedTech Industry Pulse: April 2026

Sidewinder Therapeutics and Garner Health each raised more than $250M, leading a month of mid-size rounds concentrated in drug-device therapeutics, care optimization, and MedTech AI.

Alamar Biosciences raised $191.3M through its IPO. Founded in 2018, Alamar develops instruments that detect low-level protein biomarkers in blood, enabling disease research and diagnostics.

FDA and CMS launched the RAPID Coverage Pathway on April 23, aligning the two agencies to speed Medicare coverage decisions for some Breakthrough Devices, a change worth factoring into any market access and reimbursement strategy built around a Breakthrough designation. CMS also proposed repealing the TPT/NTAP alternative pathway for breakthrough devices on April 10, restoring a substantial clinical improvement bar for add-on payments starting FY 2028. In Europe, EMA opened its Breakthrough Device pilot April 28, its first parallel to the FDA’s Breakthrough fast-track.

Senior FDA leadership turnover continued, with Commissioner Martin Makary resigning May 12. The EU AI Act deal paused compliance obligations for industrial AI but not for MedTech, keeping devices dual-regulated under both MDR and the AI Act as of May 7. EUDAMED became mandatory May 28, intensifying the EU’s push for device transparency and supply chain visibility. These leadership and framework shifts are one more reason regulatory strategy and submissions planning should build in contingency for agency turnover, not just technical requirements.

Senior FDA leadership turnover continued as Commissioner Martin Makary resigned May 12. Speed pathways opened even as compliance tightened: a Real-Time Clinical Trial pilot launched April 28, the RAPID Coverage Pathway launched April 23 for TAP participation, and CMS proposed restoring a substantial clinical improvement bar for Breakthrough Device add-on payments starting FY 2028. Separately, the new FDA quality rule became fully operational, aligning the US with ISO 13485 and giving inspectors more access, while new FDA-MITRE technical frameworks continue raising the bar for medical device cybersecurity risk analysis and software transparency.

The EU paused AI Act compliance obligations for industrial AI but not for MedTech on May 7, with the new deal postponing high-risk AI deadlines to 2027 and 2028 while granting machinery an exemption; devices remain in scope and dual-regulated under MDR and the AI Act. EMA launched its own breakthrough device fast-track April 28, Europe’s first answer to FDA’s Breakthrough pathway, with Phase I accepting Class III and high-risk Class IIb devices through May 22. EUDAMED became mandatory May 28, and manufacturer incident reporting, supply-disruption notification, and classification rules were all refreshed in April.

The UK accelerated regulatory alignment with the US on April 7, with the MHRA and FDA committing to explore mutual recognition mechanisms for medical devices and expanding the existing US-UK drugs partnership to devices. A UK consultation on recognizing EU certification closed April 10, feeding a broader international reliance strategy under which companies with approvals from the US, EU, Australia, or Canada gain streamlined UK pathways. The UK also committed £3.6M to an AI medical device sandbox on April 8, a three-year DHSC-funded program running through 2029.

Health Canada’s electronic submission system is now mandatory: all medical device license applications must use the Regulatory Enrolment Process, and paper filings are no longer accepted. Canadian submissions now share the same secure electronic gateway US sponsors use for FDA filings, operationally aligning Canada with the FDA. Health Canada also updated its AI medical device guidance, reinforcing lifecycle expectations for AI and machine learning devices.

NMPA issued five new device guidelines April 9, updating requirements for intravascular ultrasound, endoscopes, and other device categories for international alignment. China continues modernizing coverage through a shift to DRG payments, where bundled reimbursement affects total margins. A 2026 device quality crackdown launched April 8 puts more than 70 device categories under intensified inspection, with serious non-compliance now eligible for criminal charges. China also expanded its device export framework May 1, introducing a two-tier certificate system.

Australia continues tightening post-market device enforcement, with hospital adverse-event reporting penalties in effect since March 21 and expanding software rules. Japan continues to lead adaptive AI device regulation through its IDATEN and PACMP system, which permits pre-approved post-market changes for AI and machine learning software. ASEAN regulatory reliance programs continue to expand, with Malaysia and Thailand completing pilots and now operating device regulatory reliance for Class B, C, and D devices, while New Zealand maintains its TGA-aligned approach.